Evidence-based review of the nutritional treatment of obesity and metabolic dysfunction-associated steatotic liver disease in children and adolescents
- PMID: 40525381
- DOI: 10.1002/jpn3.70099
Evidence-based review of the nutritional treatment of obesity and metabolic dysfunction-associated steatotic liver disease in children and adolescents
Abstract
The growing pediatric obesity epidemic has paralleled the surge in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis. It develops due to nutritional imbalances, microbiome dysbiosis, gene regulation, hormonal changes, and environmental factors like food deserts, low activity level, and an unhealthy lifestyle. The prevalence of MASLD and obesity is rising every year. Lifestyle changes remain the mainstay treatment for obesity and MASLD. Per the 2023 American Association for the Study of Liver Diseases Practice Guidance on MASLD, achieving ≥5% weight loss can reduce hepatic steatosis, ≥7% weight loss can reduce hepatic inflammation, and ≥10% weight loss can reduce liver fibrosis. Therefore, nutritional interventions can be a powerful tool to help correct metabolic dysfunction and promote healthy weight loss. Current endorsed nutritional interventions for weight loss or MASLD include the Mediterranean diet, low glycemic/low carbohydrate diet, plant-based diet/anti-inflammatory diet, ketogenic diet, and intermittent fasting. This review provides evidence-based insights into current nutritional interventions for children and adolescents with obesity and MASLD to help guide pediatric gastroenterologists in making the best dietary-based recommendations in clinical practice.
Keywords: Mediterranean diet; intermittent fasting; ketogenic diet; low‐carbohydrate diet; plant‐based diet.
© 2025 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
References
REFERENCES
-
- Hsu CC, Ness E, Kowdley KV. Nutritional approaches to achieve weight loss in nonalcoholic fatty liver disease. Adv Nutr. 2017;8(2):253‐265. doi:10.3945/an.116.013730
-
- Asif S, Morrow NM, Mulvihill EE, Kim KH. Understanding dietary intervention‐mediated epigenetic modifications in metabolic diseases. Front Genet. 2020;11:590369. doi:10.3389/fgene.2020.590369
-
- Ministrini S, Calzini L, Nulli Migliola E, et al. Lysosomal acid lipase as a molecular target of the very low carbohydrate ketogenic diet in morbidly obese patients: the potential effects on liver steatosis and cardiovascular risk factors. J Clin Med. 2019;8(5):621. doi:10.3390/jcm8050621
-
- Bradley M, Melchor J, Carr R, Karjoo S. Obesity and malnutrition in children and adults: a clinical review. Obes Pillars. 2023;8:100087. doi:10.1016/j.obpill.2023.100087
-
- Berná G, Romero‐Gomez M. The role of nutrition in non‐alcoholic fatty liver disease: pathophysiology and management. Liver Int. 2020;40(suppl 1):102‐108. doi:10.1111/liv.14360
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical